logo
ResearchBunny Logo
Efficacy and safety of sacubitril/valsartan in heart failure compared to renin-angiotensin-aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials

Medicine and Health

Efficacy and safety of sacubitril/valsartan in heart failure compared to renin-angiotensin-aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials

A. V. Hernandez, V. Pasupuleti, et al.

This systematic review and meta-analysis revealed the impressive efficacy and safety of sacubitril/valsartan (S/V) in heart failure patients, showcasing a remarkable reduction in hospitalizations and mortality compared to ACEI or ARB. Conducted by leading researchers including Adrian V Hernandez and Vinay Pasupuleti, this research offers vital insights for improved patient outcomes.

00:00
00:00
Playback language: English
Abstract
This systematic review and meta-analysis assessed the efficacy and safety of sacubitril/valsartan (S/V) compared to ACEI or ARB in heart failure (HF) patients. Eleven RCTs (n=18766) were included. S/V reduced HF hospitalizations by 20%, CV mortality by 14%, and all-cause mortality by 11% compared to ACEI or ARB. S/V also improved biomarkers and renal function, but increased hypotension. Angioedema and hyperkalaemia events were similar between groups.
Publisher
Archives of Medical Science
Published On
May 14, 2023
Authors
Adrian V Hernandez, Vinay Pasupuleti, Nancy Scarpelli, Jack Malespini, Maciej Banach, Agata M Bielecka-Dabrowa
Tags
sacubitril/valsartan
heart failure
meta-analysis
ACEI
ARB
mortality
hospitalizations
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny